[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Pugnale N, Waridel F, Bouzourène H, Boubaker A, Pugnale M, Gaillard RC, Gomez F: Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy. Eur J Endocrinol; 2003 Mar;148(3):357-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy.
  • We report a case of a non-functioning ectopic pituitary adenoma of the rhino-pharynx studied over a long-term somatostatin analog treatment.
  • PATIENT AND TREATMENT: A 60-Year-old woman presented with severe posterior epistaxis.
  • On immunostaining, tumor cells were positive for pancytokeratins MNF 116 and C11, epithelial membrane antigen, chromogranin and neuron-specific enolase (NSE), and negative for synaptophysin, desmin, actin, estrogen and progesterone receptors, all anterior pituitary hormones and human chorionic gonadotropin.
  • Blood levels of the above hormones and tumor markers were normal, except for a moderate elevation of NSE (33.8 microg/l, normal value <12 microg/l).
  • MRI showed a normal intra-sellar pituitary gland, including the normal bright signal of the posterior lobe.
  • Somatostatin receptor scintigraphy (SRS) disclosed intense tracer uptake in the tumor, indicating high somatostatin receptor content.
  • There was also an intense uptake in the intra-sellar pituitary.
  • Therapy with long-acting octreotide was started, 20 mg per Month i.m.
  • Repeated endoscopic examinations showed rapid tumor reduction, the mass shrinkage being almost complete at 3 Months.
  • This was confirmed by MRI, while SRS showed markedly decreased uptake in the residual tumor and the intra-sellar pituitary, and NSE became normal.
  • CONCLUSION: Pharyngeal pituitary remnant adenomas are rare, but they must be considered in the differential diagnosis of bleeding or obstructive masses of the rhino-pharynx.
  • As we show for the first time in this location, octreotide can exert prolonged and marked anti-tumoral effects in non-functioning adenoma.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12611618.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Pituitary Hormones; RWM8CCW8GP / Octreotide
  •  go-up   go-down


2. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR: Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol; 2008 Mar;158(3):295-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
  • OBJECTIVE: To determine whether the somatostatin receptor subtype (SSTR) expression profile correlates with hormonal and tumor volume responses to postsurgical octreotide long acting repeatable (OCT LAR) treatment.
  • DESIGN AND METHODS: Quantitative real-time RT-PCR was used to evaluate the absolute mRNA copy numbers for all five SSTR subtypes in 22 somatotropinomas.
  • Response to OCT LAR was studied by hormone levels (GH and IGF-I) and tumor volume (sella turcica magnetic resonance imaging).
  • A positive correlation was also found between SSTR2 mRNA levels and the percentage decrease in tumor volume after 6 months of OCT LAR (r=0.79, P=0.002, n=12).
  • CONCLUSIONS: Somatostatin receptor subtype 2 mRNA expression levels in somatotropinomas correlate positively with in vivo hormonal and tumor volume responses to OCT LAR.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299461.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / NIDDK 30677
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3; 0 / somatostatin receptor 5; 0 / somatostatin receptor subtype-4; 0 / somatostatin receptor type 1; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


3. Uchino Y, Saeki N, Iwadate Y, Yasuda T, Konda S, Watanabe T, Wada K, Kazukawa I, Higuchi Y, Iuchi T, Tatsuno I, Yamaura A: Recurrence of sellar and suprasellar tumors in children treated with hGH--relation to immunohistochemical study on GH receptor. Endocr J; 2000 Mar;47 Suppl:S33-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of sellar and suprasellar tumors in children treated with hGH--relation to immunohistochemical study on GH receptor.
  • PURPOSE: GH replacement therapy is required in the majority of children with GH deficiency after treatment of sellar and suprasellar tumors.
  • Owing to the high cell proliferative ability of human GH (hGH), its influence on tumor recurrence has been debated.
  • We retrospectively studied the immunohistochemical expression of the GH receptor in various tumor tissues, in order to investigate the relation between tumor recurrence and hGH replacement.
  • METHODS: GH replacement therapy was performed in 25 patients (8 boys and 17 girls) after the treatment.
  • Tumor recurrence was noted in 4 patients (craniopharyngioma: 2 patients, pilocytic astrocytoma and germinoma: 1 each).
  • Immunohistochemical study of GH receptor in tumor tissue was carried out in those recurrent and recurrence-free cases, by using MAb 263 as a primary antibody.
  • CONCLUSION: In the patients with craniopharyngioma treated with GH, a positive immunohistochemical expression of GH receptor in tumor tissue may indicate a high probability of recurrence.
  • It is therefore speculated that each brain tumor may have its specificity in GH receptor expression.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Craniopharyngioma / drug therapy. Germinoma / drug therapy. Human Growth Hormone / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Female. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local / metabolism. Receptors, Somatotropin / metabolism. Retrospective Studies. Sella Turcica

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890179.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Receptors, Somatotropin; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


Advertisement
4. Nieder C, Schneller F, Grosu AL, Peschel C, Molls M: Radiotherapy and chemotherapy for myoepithelioma of the sellar region. Strahlenther Onkol; 2005 Apr;181(4):260-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and chemotherapy for myoepithelioma of the sellar region.
  • It is very uncommon as a primary intracranial tumor.
  • CASE REPORT: A 34-year-old African patient with proliferating myoepithelioma originating in the sellar region is described.
  • After subtotal resection, the tumor recurred locally despite postoperative radiotherapy to a total dose of 54 Gy (Figures 1 and 2).
  • When intracranial metastases developed, chemotherapy with ifosfamide and, later, BCNU was administered.
  • Uncontrolled intracranial tumor growth led to the patient's death 20 months after the initial diagnosis.
  • CONCLUSION: Most tumors of the sellar region have a favorable prognosis.
  • However, this case of incompletely resected proliferating myoepithelioma showed both local and distant recurrences, which did not respond to further treatment.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Myoepithelioma / drug therapy. Myoepithelioma / radiotherapy. Sella Turcica / radiography
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Palliative Care. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827697.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Kendi TK, Caglar S, Huvaj S, Bademci G, Kendi M, Alparslan S: Suprasellar germ cell tumor with subarachnoid seeding MRI and MR spectroscopy findings. Clin Imaging; 2004 Nov-Dec;28(6):404-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suprasellar germ cell tumor with subarachnoid seeding MRI and MR spectroscopy findings.
  • Patient had a history of depression unresponsive to drug therapy and recently developed diabetes insipidus.
  • [MeSH-major] Brain Neoplasms / diagnosis. Germinoma / diagnosis. Magnetic Resonance Imaging / methods. Neoplasm Invasiveness / pathology. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adolescent. Follow-Up Studies. Humans. Male. Risk Assessment. Sella Turcica / pathology. Sensitivity and Specificity. Subarachnoid Space / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15531139.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Gondim JA, Ferraz T, Mota I, Studart D, Almeida JP, Gomes E, Schops M: Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country. Surg Neurol; 2009 Jul;72(1):15-9; discussion 19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country.
  • Traditional treatment of acromegaly consists of surgery, drug therapy, and eventually radiotherapy.
  • We shall then argue about the economical advantages, for the NHS of a developing country, between surgical and medical treatment.
  • METHODS: We have analyzed data from 33 patients with intrasellar GH tumor who had been referred to the neuroendocrine department of the HGF, Brazil.
  • A treatment with octreotide was started for these 5 patients and resulted in an adequate control of GH and IGF-1 levels.
  • CONCLUSION: Our patients, with intrasellar GH tumor, operated by a pituitary specialist neurosurgeon had remission rates approaching those obtained by most specialized neurosurgical centers worldwide.
  • For equal results, our study shows that the surgical treatment is the best issue for the patient and for the NHS.
  • [MeSH-major] Adenoma / surgery. Endoscopy / statistics & numerical data. Growth Hormone-Secreting Pituitary Adenoma / surgery. Neurosurgical Procedures / statistics & numerical data. Sella Turcica / surgery. Sphenoid Bone / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brazil. Cost-Benefit Analysis. Developing Countries. Female. Humans. Male. Middle Aged. National Health Programs / economics. Octreotide / therapeutic use. Outcome Assessment (Health Care) / methods. Reoperation / statistics & numerical data. Retrospective Studies. Specialization / economics. Specialization / statistics & numerical data. Treatment Failure. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440607.001).
  • [ISSN] 1879-3339
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


7. Tamer G, Kartal I, Aral F: Pituitary infiltration by non-Hodgkin's lymphoma: a case report. J Med Case Rep; 2009;3:9293

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Pituitary adenomas represent the most frequently observed type of sellar masses; however, the presence of a rapidly growing sellar tumor, diabetes insipidus, ophthalmoplegia and headaches in an older patient strongly suggests metastasis to the pituitary.
  • As magnetic resonance imaging revealed a sellar mass involving the pituitary gland and infundibular stalk, which also extended into the right cavernous sinus and sphenoid sinus, the patient underwent an immediate transsphenoidal decompression surgery.
  • Paranasal sinus computed tomography scanning and magnetic resonance imaging of the thorax and abdomen were performed.
  • Since magnetic resonance imaging did not reveal any abnormality, after paranasal sinus computed tomography was performed, we concluded that the primary lymphoma originated from the sphenoid sinus and infiltrated the pituitary.
  • Chemotherapy and radiotherapy to the sellar area were planned, but the patient died and her family did not permit an autopsy.
  • CONCLUSION: Lymphoma infiltration to the pituitary is difficult to differentiate from pituitary adenoma, meningioma and other sellar lesions.
  • To plan the treatment of lymphoma infiltration of the pituitary gland, it must be differentiated from other sellar lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):574-80 [14764764.001]
  • [Cites] Pituitary. 2005;8(2):139-46 [16379034.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Int J Clin Pract. 1998 Oct;52(7):513-4 [10622097.001]
  • [Cites] Neth J Med. 1987 Apr;30(3-4):135-43 [3600898.001]
  • [Cites] Intern Med. 1994 Dec;33(12):795-8 [7718964.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):155-8 [8145058.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):69-73 [9647174.001]
  • [Cites] Haematol Blood Transfus. 1990;33:571-6 [2323657.001]
  • (PMID = 20062782.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803816
  •  go-up   go-down


8. Fukai J, Nohgawa M, Uematsu Y, Itakura T, Kamei I: Immunoglobulin D multiple myeloma involving the sella manifesting as oculomotor palsy: case report. Neurosurgery; 2010 Aug;67(2):E505-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin D multiple myeloma involving the sella manifesting as oculomotor palsy: case report.
  • OBJECTIVE: Immunoglobulin D multiple myeloma (IgD MM) is an uncommon type of MM characterized by an aggressive clinical behavior and a short survival time.
  • We report a rare case in which oculomotor palsy caused by a sellar lesion was the initial manifestation of IgD MM; systemic treatments were beneficial in this case.
  • CT scanning demonstrated a mass in the sellar and parasellar regions and partial destruction of the left side of the dorsum sellae.
  • At the time of admission, the patient had no symptoms of MM.
  • Histopathologic examination revealed a tumor consisting of plasma cells.
  • Appropriate laboratory studies, a bone scan, and a bone marrow biopsy led to a diagnosis of IgD lambda-type MM.
  • High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation was therapeutically beneficial.
  • CONCLUSION: This case demonstrates that an unusual sellar tumor might be the first manifestation of IgD MM.
  • Careful observation can suggest a possible non-pituitary etiology for a tumor, leading to appropriate diagnostic and therapeutic procedures.
  • [MeSH-major] Immunoglobulin D. Multiple Myeloma / therapy. Ophthalmoplegia / etiology. Pituitary Neoplasms / therapy. Sella Turcica / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Blood Protein Electrophoresis. Bone Marrow / pathology. Bone and Bones / pathology. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Diplopia / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Plasma Cell / surgery. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644379.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


9. Hormozi AK, Ghazisaidi MR, Hosseini SN: Unusual presentation of peripheral primitive neuroectodermal tumor of the maxilla. J Craniofac Surg; 2010 Nov;21(6):1761-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of peripheral primitive neuroectodermal tumor of the maxilla.
  • The peripheral primitive neuroectodermal tumor (pPNET) is a rare and highly malignant soft tissue neoplasm in children and young adults.
  • Two years after diagnosis, she experienced diplopia, and then magnetic resonance imaging was done, which showed a mass in the optic chiasma and parasellar region.
  • The typical appearance resembled large noncalcified soft tissue masses in the magnetic resonance image and computed tomographic scan of the maxilla.
  • Diagnosis was established by immunohistochemical features.
  • She was treated with surgery, chemotherapy, radiation therapy, and gamma knife.
  • She was under close observation since then (approximately 8 mo), and there has been no recurrence of tumor up to now.
  • [MeSH-major] Maxillary Neoplasms / diagnosis. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / secondary. Radiosurgery. Radiotherapy, Adjuvant. Sella Turcica / pathology. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119416.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sinnott BP, Hatipoglu B, Sarne DH: Intrasellar plasmacytoma presenting as a non-functional invasive pituitary macro-adenoma: case report & literature review. Pituitary; 2006;9(1):65-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 57 year old woman was referred to our department with a presumed diagnosis of a non-functioning pituitary macro-adenoma.
  • She underwent transphenoidal surgery of the sellar lesion.
  • A diagnosis of multiple myeloma was made 1 month later based on a combination of clinical, pathological and radiologic features.
  • She underwent radiation therapy directed towards the residual sellar tumor, followed by chemotherapy and autologous stem cell transplantation.
  • Review of the world literature revealed only 22 previous reports of patients in whom a solitary plasmacytoma or multiple myeloma first presented as a sellar mass; in all cases mimicking clinically and radiologically a non-functioning invasive pituitary adenoma however with additional cranial nerve involvement.
  • The diagnosis should be suspected in patients with well preserved anterior pituitary function and cranial nerve neuropathies in the presence of significant sellar destruction.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis. Plasmacytoma / diagnosis. Plasmacytoma / surgery
  • [MeSH-minor] Deamino Arginine Vasopressin / therapeutic use. Diabetes Insipidus / drug therapy. Diabetes Insipidus / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Postoperative Complications. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):653-4 [3558056.001]
  • [Cites] Br J Neurosurg. 2003 Jun;17(3):260-2 [14565527.001]
  • [Cites] Surg Neurol. 1992 May;37(5):388-93 [1631767.001]
  • [Cites] Arch Neurol. 1982 Nov;39(11):738 [7126006.001]
  • [Cites] Brain. 1954;77(1):61-81 [13160259.001]
  • [Cites] Tumori. 2001 Nov-Dec;87(6):451-4 [11989605.001]
  • [Cites] Comput Radiol. 1986 Jul-Aug;10(4):201-5 [3791987.001]
  • [Cites] Med Clin (Barc). 1982 Nov 1-15;79(8):377-9 [6816996.001]
  • [Cites] Arch Neurol. 1963 Nov;9:534-44 [14057685.001]
  • [Cites] J Clin Neurosci. 2002 Sep;9(5):586-9 [12383423.001]
  • [Cites] Lancet. 1967 Dec 23;2(7530):1354-6 [4170040.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):218-21 [7616264.001]
  • [Cites] Postgrad Med J. 1985 Jun;61(716):513-4 [4011536.001]
  • [Cites] Cancer. 1979 Apr;43(4):1513-5 [445346.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):55-6 [576202.001]
  • [Cites] Surg Neurol. 1980 Sep;14(3):233-6 [7001658.001]
  • [Cites] Bull Soc Ophtalmol Fr. 1981 Mar;81(3):355-6 [7226412.001]
  • [Cites] Pathol Oncol Res. 2003;9(2):134-7 [12858221.001]
  • [Cites] Australas Radiol. 2001 May;45(2):244-6 [11380375.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] J Neuroophthalmol. 1996 Sep;16(3):199-203 [8865015.001]
  • [Cites] Arch Neurol. 1992 May;49(5):555-8 [1580820.001]
  • [Cites] Endocr Pract. 1998 Nov-Dec;4(6):382-6 [15251713.001]
  • [Cites] Ital J Neurol Sci. 1994 Oct;15(7):369-72 [7698896.001]
  • [Cites] Rinsho Ketsueki. 1996 Mar;37(3):260-4 [8727353.001]
  • [Cites] Neurol Neurochir Pol. 1991 Sep-Oct;25(5):683-8 [1808532.001]
  • [Cites] Neurochirurgie. 1991;37(1):67-71 [2017297.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Aug;47(4):230-4 [15346320.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Jan;47(1):99-100 [6693924.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3455-9 [8855784.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2637-45 [15602025.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1201-3 [9298068.001]
  • [Cites] Pituitary. 2004;7(3):179-181 [16328566.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):219-20 [10189508.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1513-7 [1540888.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Br J Neurosurg. 1991;5(4):405-7 [1786137.001]
  • [Cites] No Shinkei Geka. 2001 Jun;29(6):551-7 [11452502.001]
  • (PMID = 16703411.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] ENR1LLB0FP / Deamino Arginine Vasopressin
  • [Number-of-references] 42
  •  go-up   go-down


11. Okuguchi T, Wada T, Yoshida Y, Beppu T, Arai H, Ogasawara K, Suzuki M, Ogawa A: [A case of intrasellar pure germinoma]. No Shinkei Geka; 2000 Mar;28(3):263-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 19-year-old male presented with progressive loss of vision and diabetes insipidus due to an intra- and suprasellar tumor.
  • Seven days after the operation, bleeding from the residual tumor caused headache and right occulomotor palsy.
  • The residual tumor and hematoma were removed using pterional approach.
  • The residual tumor disappeared after postoperative irradiation.
  • Adjuvant chemotherapy and whole supratentorial irradiation were performed.
  • Mid-sagittal magnetic resonance image was useful in our patient for differential diagnosis between intrasellar germinoma and pituitary adenoma.
  • We notice that transsphenoidal surgery should be selected for treatment of postoperative bleeding from intrasellar germinoma.
  • [MeSH-major] Germinoma / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology
  • [MeSH-minor] Adenoma / diagnosis. Adult. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Hypophysectomy / methods. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10721527.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


12. Kuge A, Kayama T, Tsuchiya D, Kawakami K, Saito S, Nakazato Y, Suzuki H: [Suprasellar primary malignant rhabdoid tumor in an adult: a case report]. No Shinkei Geka; 2000 Apr;28(4):351-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Suprasellar primary malignant rhabdoid tumor in an adult: a case report].
  • Malignant rhabdoid tumor (MRT), described for the first time in 1978 in the kidney, has rarely been reported in other organs including the brain and has involved adults in only 3 cases.
  • Subtotal removal of the tumor was performed.
  • However, tumor regrowth occurred after the operation (doubling time, 8.36 days) and spinal dissemination was detected.
  • Therefore, chemotherapy and radiotherapy were administered focusing on the suprasellar lesion and the spinal cord.
  • Optimal treatment for this tumor has not been established.
  • Our case may be useful in defining treatment for MRT.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Sella Turcica

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769834.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


13. Gomez-Daspet J, Elko L, Grebenev D, Vesely DL: Survival with serum sodium level of 180 mEq/L: permanent disorientation to place and time. Am J Med Sci; 2002 Dec;324(6):321-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival with serum sodium level of 180 mEq/L: permanent disorientation to place and time.
  • A 41-year-old woman who had undergone transfrontal craniotomy for a pituitary tumor 4 months before presentation was admitted with confusion and orientation only to self.
  • Measured serum osmolality was 380 mOsmol/L with a urine osmolality of 360 mOsmol/L.
  • Magnetic resonance imaging revealed a 1.5-cm mass in the sella turcica, which was nonfunctioning on endocrine evaluation.
  • However, she developed permanent (6 months) disorientation to time and place even when hypernatremia was corrected, which has not been described previously.
  • [MeSH-minor] Adult. Craniopharyngioma / surgery. Deamino Arginine Vasopressin / therapeutic use. Diabetes Insipidus, Neurogenic / complications. Diabetes Insipidus, Neurogenic / diagnosis. Diabetes Insipidus, Neurogenic / drug therapy. Diabetes Insipidus, Neurogenic / pathology. Female. Humans. Magnetic Resonance Imaging. Pituitary Gland / pathology. Pituitary Gland / physiopathology. Pituitary Neoplasms / surgery. Renal Agents / therapeutic use. Sella Turcica

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12495299.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Renal Agents; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


14. Xie J, Luo SQ, Ma ZY, Zhang YQ, Zeng HY, Qiu XG: [The clinical features and treatment of intracranial tumors in infants]. Zhonghua Yi Xue Za Zhi; 2004 Aug 2;84(15):1270-5
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features and treatment of intracranial tumors in infants].
  • OBJECTIVE: To explore the treatment plan of intracranial tumors in infants.
  • The total removal of tumor was 72.0%, subtotal removal 17.5%, partial removal 10.5%.
  • RESULTS: The tumor located at posterior fossa (37.7%), sella region (31.6%), hemisphere (19.3%) including in basal ganglia.
  • But 6 patients developed worse than the children of the same age.
  • Although radiotherapy is useful of inhibiting the growth of tumor, the dosage should be decreased for infants and the complications in long term also should be considered simultaneously.
  • It is a trend towards performing chemotherapy after operation.
  • It is not necessary to perform auxiliary therapy for astrocytoma, oligodendroglioma, and mixed glioma, because the prognosis is good after total removal of the tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Microsurgery
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / surgery. Child, Preschool. Cranial Fossa, Posterior. Female. Follow-Up Studies. Humans. Infant. Male. Medulloblastoma / diagnosis. Medulloblastoma / surgery. Retrospective Studies. Sella Turcica

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15387964.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Arita K, Sugiyama K, Tominaga A, Yamasaki F: Intrasellar rhabdomyosarcoma: case report. Neurosurgery; 2001 Mar;48(3):677-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors encountered a patient with an intrasellar rhabdomyosarcoma with no evidence of tumor at any additional sites.
  • The patient was diagnosed as having a sellar tumor invading the left cavernous sinus.
  • INTERVENTION: Near total removal of the tumor was achieved via a trans-sphenoidal approach.
  • Histologically, the tumor was composed of small, round-to-elongated undifferentiated cells and large spindle cells with myoblastic features.
  • Immunohistochemically, tumor cells were positive for antibodies against desmin, myoglobin, and alpha-smooth muscle actin.
  • The tumor was identified as an embryonal rhabdomyosarcoma on the basis of the above pathological findings.
  • Postoperative local radiation therapy and chemotherapy with the use of ifosfamide, etoposide, and vincristine brought about complete initial remission.
  • CONCLUSION: Rhabdomyosarcoma should be considered in the differential diagnosis of a primary intrasellar neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Sella Turcica

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11270561.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Okamoto S, Kurimoto M, Hirashima Y, Hayashi N, Kuwayama N, Endo S, Okada E, Ishizawa S: [Systemic non-Hodgkin lymphoma initially presented with visual disturbance due to intrasellar lymphoma--a case report]. No Shinkei Geka; 2001 Jan;29(1):59-63
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case with systemic non-Hodgkin lymphoma involving the sella turcica and kidney is reported.
  • MRI showed a contrast-enhancing mass in the sella turcica.
  • The tumor extended to the right optic nerve.
  • The slightly firm, fibrous and vascular-rich tumor was subtotally removed.
  • The histopathological examination revealed a malignant lymphoma, diffuse-large-cell type with B-cell phenotype.
  • The patient received radiation therapy and the tumor disappeared.
  • However, the patient suddenly died of acute heart failure with unknown cause just before starting chemotherapy for systemic lymphoma.
  • [MeSH-minor] Aged. Humans. Kidney Neoplasms / pathology. Magnetic Resonance Imaging. Male. Sella Turcica / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218768.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Janmohamed S, Grossman AB, Metcalfe K, Lowe DG, Wood DF, Chew SL, Monson JP, Besser GM, Plowman PN: Suprasellar germ cell tumours: specific problems and the evolution of optimal management with a combined chemoradiotherapy regimen. Clin Endocrinol (Oxf); 2002 Oct;57(4):487-500
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Suprasellar germ cell tumours are rare, and there are few series of patients outlining the problems in diagnosis and management, and providing clear guidelines for optimal therapy.
  • PATIENTS AND DESIGN: A retrospective case review assessment of all patients seen within a given time.
  • Clinical, biochemical and radiological findings were reviewed, the types of therapy administered noted, and the responses to treatment analysed.
  • The median age at presentation was 20 years (range 6-49 years) with a median duration of symptoms before diagnosis of 17 months (range 1-35 months).
  • Positron emission tomography scanning was occasionally useful in the evaluation of suprasellar tumours/pituitary stalk lesions deemed too risky to biopsy.
  • Treatment did not correct previously abnormal endocrine function although it did improve vision in three of six patients.
  • CONCLUSIONS: We therefore emphasize the use of techniques other than biopsy in the diagnosis of these patients, note the problems in the management of their fluid control, and highlight the favourable response to a combined chemotherapy-radiotherapy protocol.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy. Sella Turcica
  • [MeSH-minor] Adolescent. Adult. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Diabetes Insipidus / etiology. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12354131.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Prabhu SS, Aldape KD, Gagel RF, Benjamin RS, Trent JC, McCutcheon IE: Sarcomatous change after sellar irradiation in a growth hormone-secreting pituitary adenoma. Can J Neurol Sci; 2003 Nov;30(4):378-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatous change after sellar irradiation in a growth hormone-secreting pituitary adenoma.
  • BACKGROUND: Although the benefits of radiotherapy for pituitary adenomas are well-documented, post-irradiation sarcomas of the sella are rarely seen, with only 20 cases (mainly of fibrosarcoma) reported in the medical literature.
  • METHOD: We describe a case of post-irradiation sarcoma five years after surgery followed by external-beam irradiation for an extensive and locally invasive growth hormone-secreting tumor.
  • RESULTS: The patient underwent transsphenoidal resection of the recurrent tumor, followed by adjuvant chemotherapy.
  • This led to significant relief in the patient's symptoms including radiological evidence of tumor shrinkage, but the tumor regrew when, owing to dose-limiting toxicity, chemotherapy was stopped.
  • They should be suspected in patients following sellar irradiation who show abrupt onset of new symptoms and appropriate radiological findings, and such tumors may respond to cytotoxic chemotherapy.
  • [MeSH-minor] Adult. Humans. Male. Sella Turcica / pathology. Sella Turcica / radiation effects

  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14672272.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


19. Starzyk J, Starzyk B, Bartnik-Mikuta A, Urbanowicz W, Dziatkowiak H: Gonadotropin releasing hormone-independent precocious puberty in a 5 year-old girl with suprasellar germ cell tumor secreting beta-hCG and alpha-fetoprotein. J Pediatr Endocrinol Metab; 2001 Jun;14(6):789-96
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotropin releasing hormone-independent precocious puberty in a 5 year-old girl with suprasellar germ cell tumor secreting beta-hCG and alpha-fetoprotein.
  • Tumor markers beta-hCG and AFP were markedly elevated and a 2.5 x 1.5 cm suprasellar germ cell tumor (GCT) was visualized by MRI.
  • Combined chemotherapy followed by radiotherapy resulted in normalization of pubertal features along with estrogen and marker levels.
  • Our observations support the possibility of hCG-dependent precocious puberty (PP) in girls caused by suprasellar hCG-secreting tumor.
  • We hypothesize that the rarity of isosexual PP in girls with hCG-secreting suprasellar GCT results not only from the lower occurrence of these tumors in girls than in boys, but above all from a rare simultaneous concomitant incidence of both high tumor aromatase activity and hCG secreting potency.
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Sella Turcica

  • Genetic Alliance. consumer health - Precocious puberty.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11453531.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


20. Abdullah SH, Irie K, Oi S: Rapidly growing giant suprasellar tumor in a high-risk child: treatment strategy and role of neuroendoscopic surgery in slit-like ventricles. Childs Nerv Syst; 2006 Apr;22(4):403-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing giant suprasellar tumor in a high-risk child: treatment strategy and role of neuroendoscopic surgery in slit-like ventricles.
  • METHODS: We present a case of a 10-year-old girl treated with therapeutic anticoagulation for previous cardiac valvular replacement, who presented with rapidly growing giant (>4 cm) suprasellar germinoma.
  • "Oi-Samii Handy Pro" made it possible to obtain the tissue diagnosis.
  • RESULTS: Complete remission was achieved using neoadjuvant chemotherapy, minimally invasive neuroendoscopic surgery, then followed by specific chemoradiotherapy.
  • CONCLUSION: The role of neuroendoscopic procedure, performed in a difficult situation with normalized size of the ventricles, was emphasized.
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures / methods. Sella Turcica. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 1999 Dec;12(6):693-6 [10676750.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):185-90 [9892101.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):36-40 [9548339.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):857-65 [11821471.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):487-500 [12354131.001]
  • [Cites] Surg Neurol. 1996 Oct;46(4):370-7 [8876719.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):71-80 [9049865.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):211-7 [11767288.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):245-53 [10930010.001]
  • [Cites] No Shinkei Geka. 2002 Sep;30(9):935-42 [12233091.001]
  • [Cites] Neurosurg Rev. 1995;18(4):285-92 [8927248.001]
  • [Cites] Nihon Jinzo Gakkai Shi. 1999 Dec;41(8):804-12 [10655729.001]
  • [Cites] Neurol India. 2000 Dec;48(4):381-4 [11146607.001]
  • [Cites] Pediatr Neurosurg. 1998 Jul;29(1):19-22 [9755307.001]
  • [Cites] Endocr J. 1999 Apr;46(2):263-7 [10460010.001]
  • [Cites] Childs Nerv Syst. 1998 Oct;14(10):596-601 [9840386.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Mar;33(3):152-7 [7683121.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):113-8 [16206745.001]
  • [Cites] Acta Neurochir (Wien). 1992;114(1-2):26-32 [1561935.001]
  • [Cites] Childs Nerv Syst. 1990 Mar;6(2):86-91 [2340534.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):340-4 [2910439.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1999 Dec;62(12):859-66 [10633999.001]
  • (PMID = 16075215.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


21. Yaman E, Benekli M, Coskun U, Sezer K, Ozturk B, Kaya AO, Yildiz R, Uluoglu O, Buyukberber S: Intrasellar plasmacytoma: an unusual presentation of multiple myeloma. Acta Neurochir (Wien); 2008 Sep;150(9):921-4; discussion 924
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Plasmacytomas are unusual causes of a sellar mass.
  • Initial diagnosis of a nonfunctioning pituitary adenoma was later overruled by a repeat biopsy, which showed a plasmacytoma.
  • The tumor stained positively for CD138 and kappa light chain.
  • Further studies confirmed the diagnosis of multiple myeloma.
  • The patient was successfully treated with radiotherapy followed by systemic chemotherapy.
  • Because they have different therapeutic implications, extramedullary plasmacytomas involving pituitary gland should be considered in the differential diagnosis of a nonfunctioning pituitary mass.
  • [MeSH-major] Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / etiology. Plasmacytoma / diagnosis. Plasmacytoma / etiology
  • [MeSH-minor] Adenoma / diagnosis. Aged. Biopsy. Diagnosis, Differential. Female. Humans. Immunoglobulin kappa-Chains / metabolism. Magnetic Resonance Imaging. Sella Turcica. Syndecan-1 / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726062.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Syndecan-1
  • [Number-of-references] 24
  •  go-up   go-down


22. Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL: Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab; 2006 Dec;91(12):4776-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECT: The patient was a 44-yr-old woman who was diagnosed with a biopsy-proven metastatic pulmonary endocrine tumor during pregnancy.
  • After delivery, she underwent radiation and chemotherapy for pulmonary and skeletal metastases.
  • Her disease was clinically stable for 7 yr until she developed bitemporal hemianopia.
  • RESULTS: Magnetic resonance imaging (MRI) of the brain confirmed the presence of a 2.6-cm lesion within the sella turcica extending above the sella and compressing the optic chiasm.
  • The patient underwent uneventful transsphenoidal resection of the sellar tumor.
  • Histological examination confirmed metastatic endocrine carcinoma to the pituitary, and immunohistochemistry localized GHRH to the tumor cells.
  • CONCLUSION: This is the first report of a GHRH-producing endocrine tumor metastasizing to the pituitary and causing local hyperstimulation with somatotroph hyperplasia and adenomatous transformation.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968791.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones, Ectopic; 0 / Indium Radioisotopes; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


23. Gori G, Spinelli G, Spinelli C, Tuccori M, Blandizzi C, Del Tacca M: Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia. Nat Rev Gastroenterol Hepatol; 2010 Nov;7(11):642-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 37-year-old female, who had a neuroendocrine pancreatic neoplasm, underwent duodeno-cephalo-pancreatectomy.
  • In the 2 years following surgery, she had normal levels of serum chromogranin A (CgA), gastrin and other tumor markers.
  • About 3 years after surgery, owing to the onset of reflux-like dyspeptic symptoms, the patient started treatment with the PPI esomeprazole.
  • During PPI treatment, the patient's serum CgA level rose to more than three times the upper limit of normal, although her gastrin levels remained in the normal range.
  • These findings were interpreted as being suggestive of neuroendocrine tumor relapse.
  • INVESTIGATIONS: Thoraco-abdominal CT, In¹¹¹-octreotide total body scan, CT of sella turcica, Tc(99m)-sestamibi neck scan, mutational analysis of chromosome 11q13 (site of multiple endocrine neoplasia type 1 [MEN1] gene).
  • DIAGNOSIS: Esomeprazole-induced hyperchromograninemia in the absence of elevated levels of fasting serum gastrin.
  • MANAGEMENT: Discontinuation of acid-suppressive treatment and continuation of oncologic follow-up.
  • [MeSH-major] Anti-Ulcer Agents / adverse effects. Chromogranin A / blood. Esomeprazole / adverse effects. Gastrins / blood. Gastroesophageal Reflux / drug therapy

  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938461.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Chromogranin A; 0 / Gastrins; N3PA6559FT / Esomeprazole
  •  go-up   go-down


24. Castro MR, Kocher D, Morris JC: An unusual case of inappropriate secretion of thyrotropin: neoplastic or nonneoplastic? Endocr Pract; 2000 Jan-Feb;6(1):29-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MRI of the pituitary was negative for tumor during a 2-year period, and octreotide scan was also negative for sellar uptake.
  • CONCLUSION: This patient had clinical symptoms of hyperthyroidism associated with some features characteristic of nIST (increased level of SHBG, lack of thyrotropin response to TRH stimulation, absence of thyroid receptor b mutations) and others typical of nnIST (normal alpha subunit and its molar ratio to thyrotropin, absence of tumor on sellar imaging).
  • Close follow-up with periodic MRI of the sella is important because of the possible existence of a small pituitary tumor, which may become apparent at a later date.
  • Therapy to control symptoms is important.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / secretion. Pituitary Diseases / diagnosis. Pituitary Diseases / physiopathology. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secretion. Thyrotropin / secretion
  • [MeSH-minor] Adult. Diagnosis, Differential. Drug Resistance. Humans. Hyperthyroidism / etiology. Hyperthyroidism / surgery. Magnetic Resonance Imaging. Male. Thyroid Gland / pathology. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11419924.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  • [Number-of-references] 18
  •  go-up   go-down


25. Fassett DR, Couldwell WT: Metastases to the pituitary gland. Neurosurg Focus; 2004 Apr 15;16(4):E8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiation of pituitary metastasis from other pituitary tumors based on neuroimaging alone can be difficult, although certain features, such as thickening of the pituitary stalk, invasion of the cavernous sinus, and sclerosis of the surrounding sella turcica, can indicate metastasis to the pituitary gland.
  • Differentiating metastasis to the pituitary gland from bone metastasis to the skull base, which invades the sella turcica, can also be difficult.
  • In metastasis to the pituitary gland, surrounding sclerosis in the sella turcica is usually minimal compared with metastasis to the skull base.
  • Treatment for these tumors is often multimodal and includes surgery, radiation therapy, and chemotherapy.
  • Tumor invasiveness can make resection difficult.
  • Although surgical series have not shown any significant survival benefits given by tumor resection, the patient's quality of life may be improved.
  • [MeSH-major] Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging / methods. Humans. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191337.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


26. Zárate A, Saucedo R, Basurto L: [The best approach to treat prolactinoma]. Gac Med Mex; 2004 Sep-Oct;140(5):567-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prolactinoma is the most frequent pituitary tumor; the clinical presentation in women is characterized by menstrual disorders, amenorrhea, galactorrhea and/or sterility; neurological symptoms are present only when the tumor exceeds the sella turcica which is exceptional.
  • The first therapeutical option is dopamine agonist drugs, thus surgery has been practically eliminated.
  • Dopaminergic drugs suppress both synthesis and prolactin secretion, which in turn restores the ovarian function and induces tumor shrinkage.
  • In conclusion, dopamine agonists constitute the prolactinoma treatment; in addition drug withdrawal is followed by remission of prolactinoma activity.
  • In men, the size of the prolactinoma is larger, macroprolactinoma which usually presents extrasellar extension accompanied of neurological and visual symptoms; however the prolactinoma exhibits a favorable response with dopaminergic drugs.
  • [MeSH-major] Dopamine Agents / therapeutic use. Pituitary Neoplasms / drug therapy. Prolactinoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15559242.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Dopamine Agents; 9002-62-4 / Prolactin
  •  go-up   go-down


27. Kowalewska B, Krywejko J, Roszkowska E: [Efficacy of rituximab in refractory Wegener's granulomatosis with central nervous system involvement]. Ann Acad Med Stetin; 2010;56 Suppl 1:99-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three major mechanisms have been implicated in CNS involvement accompanying WG: contiguous growth of granuloma from extracranial sites (e.g., paranasal sinuses), intracranial granuloma (tumor) formation, and vasculitis.
  • CASE REPORT: We present the case of a 38-year-old woman with a severe form of WG that was refractory to standard therapy.
  • Cranial MRI revealed infiltration of dura mater at the sella turcica near the left cavernous sinus and infiltration in the left orbital apex surrounding the optic nerve.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Granulomatosis with Polyangiitis / drug therapy. Granulomatosis with Polyangiitis / epidemiology. Nervous System Diseases / drug therapy. Nervous System Diseases / epidemiology
  • [MeSH-minor] Adult. Causality. Comorbidity. Female. Humans. Immunologic Factors / therapeutic use. Magnetic Resonance Imaging. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Wegener's granulomatosis.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21365953.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. Lindstedt G, Lundberg PA, Jakobsson KE, Tägnfors U, Janson PO: [Don't miss prolactinoma! On the importance of measuring prolactin and how it is done]. Lakartidningen; 2000 Jan 26;97(4):333-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolactinoma is the most common functional pituitary tumor.
  • Since appropriate treatment is often pharmacological rather than surgical, all patients with a tumor within or close to the sella turcica should be evaluated for prolactinoma before being sent for neurosurgery.
  • [MeSH-major] Biomarkers, Tumor / blood. Pituitary Neoplasms / blood. Prolactin / blood. Prolactinoma / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10684228.001).
  • [ISSN] 0023-7205
  • [Journal-full-title] Läkartidningen
  • [ISO-abbreviation] Lakartidningen
  • [Language] swe
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] SWEDEN
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Prolactin; 9002-62-4 / Prolactin
  • [Number-of-references] 21
  •  go-up   go-down


29. Seiz M, Radek M, Buslei R, Kreutzer J, Hofmann B, Kottler U, Doerfler A, Nimsky C, Fahlbusch R: Alveolar rhabdomyosarcoma of the clivus with intrasellar expansion: Case report. Zentralbl Neurochir; 2006 Nov;67(4):219-22
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a primarily intracranial localization of this tumor entity is rare.
  • We report on a 3-year-old boy presenting with double vision due to left VI (th) nerve palsy.
  • Transsphenoidal biopsy was performed and histopathological examination as well as molecular diagnostics confirmed the diagnosis of an alveolar rhabdomyosarcoma (ARMS).
  • Staging identified a metastatic lesion in the fourth thoracic vertebra resulting in the diagnosis of stage IV disease.
  • Treatment modality included stereotactic radio- and chemotherapy.
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Abducens Nerve Diseases / pathology. Adrenocorticotropic Hormone / deficiency. Angiography. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Carboplatin / administration & dosage. Child, Preschool. Etoposide / administration & dosage. Human Growth Hormone / deficiency. Humans. Magnetic Resonance Imaging. Male. Radiosurgery. Sella Turcica / pathology. Sella Turcica / surgery. Spine / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139605.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 12629-01-5 / Human Growth Hormone; 6PLQ3CP4P3 / Etoposide; 9002-60-2 / Adrenocorticotropic Hormone; BG3F62OND5 / Carboplatin
  •  go-up   go-down


30. Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L: Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary; 2010;13(1):54-9
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
  • We report the case of a 60 year old male who complained of headache and blurry vision--that progressed to left ophthalmoplegia and ptosis--after receiving a dose of leuprolide for Prostate cancer therapy.
  • Imaging showed a hemorrhagic sellar mass.
  • The patient underwent transsphenoidal debulking, and the tissue obtained demonstrated immunohistochemical staining for LH.
  • A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer.
  • In most cases, the sellar tissues stained for LH, consistent with a gonadotropinoma.
  • Particular attention to clinical findings suggestive of a non functioning pituitary tumor in patients receiving GnRH agonist therapy is critical as routine screening with MRI is not practical.
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Humans. Male. Middle Aged. Prostatic Neoplasms / complications. Prostatic Neoplasms / drug therapy. Sella Turcica


31. Mah PM, Webster J: Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med; 2002 Nov;20(4):365-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperprolactinemia: etiology, diagnosis, and management.
  • A prolactinoma is the most common cause of chronic hyperprolactinemia once pregnancy, primary hypothyroidism, and drugs that elevate serum prolactin levels have been excluded.
  • Patients can present with hypogonadism, infertility, galactorrhea, osteopenia, and mass effects of the tumor.
  • This involves a careful history and examination, followed by laboratory tests and diagnostic imaging of the sella turcica.
  • The goals of treatment are to normalize prolactin levels, restore gonadal function, and reduce the effects of chronic hyperprolactinemia.
  • Dopamine agonists are the treatment of choice for the majority of patients.
  • However, there are more data on the safety of the latter drug during pregnancy and bromocriptine, therefore, remains the treatment of choice in hyperprolactinemic women wishing to conceive.
  • [MeSH-major] Hyperprolactinemia / diagnosis. Hyperprolactinemia / therapy
  • [MeSH-minor] Bromocriptine / therapeutic use. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Humans. Neurosurgical Procedures. Prevalence

  • Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12536359.001).
  • [ISSN] 1526-8004
  • [Journal-full-title] Seminars in reproductive medicine
  • [ISO-abbreviation] Semin. Reprod. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 3A64E3G5ZO / Bromocriptine; LL60K9J05T / cabergoline
  • [Number-of-references] 46
  •  go-up   go-down






Advertisement